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 In cellular MRI, micrometer-sized iron oxide particles (MPIO) are a more sensitive 
contrast agent for tracking inflammatory-cell migration compared to ultra-small 
superparamagnetic iron oxide particles (USPIO). Inflammation, which promotes adverse 
tissue remodeling, is known to occur in the viable myocardium adjacent to the necrosed 
area after a myocardial infarction (MI). This study investigated the temporal relationship 
between inflammatory cell infiltration and cardiac function during tissue remodeling 
post-MI using MPIO-enhanced MRI. The MPIO were injected into 7 C57Bl/6 mice 
(MI+MPIO group) via intravenous administration. The MI was induced 7 days post-
MPIO injection. As control groups, 7 mice (Sham+MPIO group) underwent sham-
operated surgery without myocardial injury post-MPIO injection and another 6 mice (MI-
MPIO group) underwent MI surgery without MPIO injection. MRIs performed post-MI 
showed a significant signal attenuation at the MI zone in the MI+MPIO group compared 
to the control groups. The findings suggested that the inflammatory cells containing 
MPIO infiltrated into the myocardial injury site. Cardiac function was also measured and 
correlated with the labeled-cell infiltration at the MI site. This study demonstrated a 
noninvasive technique for monitoring inflammatory cell migration using the MPIO 
contrast agent. This MPIO-enhanced MRI technique could provide additional insight 










With the advent of novel contrast agents and cell labeling techniques, the potential of 
using MRI as a noninvasive tool to in vivo detect the localization [1, 2], distribution  [3-5] 
and migration [6, 7] of contrast agent labeled cells has recently been widely studied and 
evaluated. Iron oxide particles, which predominantly cause signal reduction in T2
*- and 
T2-weighted images, have been applied as negative enhanced contrast agents to a variety 
of animal models in molecular and cellular imaging [8]. Some of them have the potential 
of translation from preclinical to clinic diagnostic application.  
1.1 MRI and Contrast Agents 
MRI is now playing an important role in medical imaging. Its power in diagnostic 
arena of patient care is unquestionable. MRI is a powerful imaging modality primarily 
because of its advantage in the soft tissue contrast. This advantage has been further 
consolidated with the advent of all kinds of contrast agents. The other excitement about 
MRI is its characteristic of relative safety. Being a noninvasive technique, the MRI 
employs magnetic fields, which is considered safe at a range of up to 3 Tesla, other than 
any radiation beam or radionuclide to form the basic principles of imaging. 
Generally, MRI provides high contrast-to-noise ratio (CNR) on the appropriate T1-, 
T2- or proton density-weighted image. In most cases the contrast is sufficient to 
distinguish pathological from healthy tissue. However, in the situations that the inherent 
contrast could not provide enough differentiation, contrast agents can be used to increase 




are categorized as two classes: paramagnetic contrast agents and superparamagnetic 
contrast agents, as shown in Table 1.1.  
 
 
Table 1.1: Classification of MRI contrast agents 
 Paramagnetic Superparamagnetic 
T1 Effect Strong Weak 
T2 Effect Weak Strong 
MRI sequence T1-weighted T2-weighted 
Signal intensity Hyperintensity Hypointensity 




The paramagnetic contrast agents primarily shorten T1 value of the targeted tissue and 
hence render a hyperintense area corresponding to the targeted tissue in the T1-weighted 
image. Paramagnetic contrast agents are based on metal ions, such as gadolinium (Gd), 
manganese (Mn) or europium (Eu), that have a large number of unpaired electrons. The 
most commonly used clinical paramagnetic contrast agent is gadolinium 
diethylenetriaminepentaacetic acid (Gd-DTPA).  
The Superparamagnetic agents are also called ferromagnetic agents, and primarily 
shorten T2 and T2
* values of the targeted tissue. They render a hypointense area 
corresponding to the tissue with contrast agents accumulation in the T2- or T2
*-weighted 
image. The superparamagnetic contrast agents consist of small magnetic particles 
containing iron, and are also referred as superparamagnetic iron oxide particles. The 
superparamagnetic iron oxide particles usually consist of a crystalline core comprising a 




have a much higher magnetic moment due to the electron spin coupling in the crystal 
lattice. They are able to cause inhomogeneity in the local magnetic field and therefore 
render a shorter T2
* value.  
1.2 Iron Oxide Particles 
Iron oxide particles, which predominantly cause signal reduction in T2
*- and T2-
weighted images as mentioned above, have been applied as negative enhanced contrast 
agents to a variety of animal models in molecular and cellular imaging [9]. The 
applications employing iron oxide particles as MRI contrast agent include detection of 
liver tumors [10-12], lymph node metastases [13-15], inflammatory and degenerative 
diseases associated with high macrophage activity [16-18]. Several distinct classes of iron 
oxide particles have widely been used [19] and categorized by size mainly as 
micrometer-sized iron oxide particles (MPIO, with micrometer diameter) [20-24], small 
superparamagnetic iron oxide particles (SPIO, with hundreds of nanometer diameter) 
[25-27] and ultra-small superparamagnetic iron oxide particles (USPIO, with tens of 
nanometer diameter) [28-31]. In some cases monocrystalline iron oxide nanoparticles 
(MION) are also used. Two iron oxide compounds have been commercialized for 
intravenous use: Ferumoxides and Ferucarbotran, both with liver tumors as the clinical 
targets. Ferumoxides are coated with dextran and  Ferucarbotran  with carboxydextran. 
The iron oxide particles are readily taken up by macrophages [32], which results in 
their accumulation in the macrophage-rich organs such as liver, spleen, bone marrow and 
lymphatic nodes [33, 34] following injection. The physicochemical characteristics of the 
iron oxide particles such as the size, charge, coating, etc, not only affect their imaging 




applied subjects [8, 35, 36]. The blood half-lives for iron oxide particles are dose 
dependent and also relate to a progressive saturation of macrophage uptake by the liver or 
other macrophage-rich organs.  For example, the blood half-life of ferumoxtran-10 is 2 to 
3 hours in rat and 24 to 36 hours in human at doses of 30 or 45 mol Fe/kg body weight.     
Although the iron oxide uptake by macrophages is well approved by both the in vitro 
and in vivo studies, the pathways of transporting iron oxide particles to the local 
macrophages in the targeted tissue are not clearly defined. There are several pathways 
potentially existing [16, 37, 38]. The microspheres could be endocytosed by activated 
blood monocytes which migrate into pathological tissues. They could also be 
transcytosed across the endothelium by in situ macrophages followed by progressive 
endocytosis. Furthermore, they could be transported into the pathological tissue via the 
inflammatory neovasculature, with both aforementioned mechanisms involved 
simultaneously.  
One of the common and important applications in iron oxide contrast agents-
enhanced MRI is to examine the inflammation process in which macrophages play an 
important role. Macrophages are able to phagocytose iron oxide particles and home to the 
disease site. Consequently the iron oxide particle-laden macrophages could be detected 
and monitored temporally by MRI during the inflammation process. For instance, the iron 
oxide particles have been used to detect ischemia-associated inflammation [38-41], 
macrophage-rich atherosclerosis [17, 42, 43], and acute cardiac graft rejection [44, 45]. 
Recently, MPIO have been studied to evaluate their potential for magnetic resonance 




The size difference among iron oxide particles can lead to significant differences in 
their abilities to alter the T2 relaxation rate R2. T1 and T2 relaxation rate (R1 and R2) are 
defined as the inverse of T1 and T2 relaxation time (R1 = 1/T1 and R2 = 1/T2), respectively. 
Furthermore, it can also cause a very different plasma half-life and biodistribution in the 
subject.   
As the study performed in 1.0% agarose gel at 0.47 T over a range of 0-1.0 mM Fe by 
Williams et al [32], the relaxation rate R2 of MPIO exhibits a concentration dependency 
as high as 82.8 second-1mM-1, which is much higher than that of USPIO. Furthermore, for 
MPIO, there was little or no dependency of T1 relaxation rate on iron content in the 
preparation (1.2 second-1mM-1). This property of MPIO provides advantage over USPIO 
in largely reducing the T2 relaxation time without mixing much T1 effect.  
When it comes to the cell labeling and cellular imaging, MPIO labeling can cause 
greater signal attenuation than smaller particle labeling. Considering the large iron 
content of MPIO, fewer particles are necessary for sufficient signal attenuation in order to 
track the labeled cells. It was demonstrated that single cells loaded with single MPIO can 
be detected [46]. In contrast, accumulation of a considerable number of USPIO in one 
cell was required to achieve sufficient image contrast [47, 48]. Furthermore, the cell 
division will dilute the USPIO concentration in the daughter cells and lead to the loss of 
cell tracking. The MPIO overcome the dilution effect in cell tracking because single 
MPIO could cause enough signal attenuation. At last, MPIO also render a fast blood pool 
clearance following the intravenous injection than USPIO, which can potentially shorten 




sensitivity of MPIO opens up possibilities for in vivo tracking of MPIO labeled cells. To 
date, however, none of the MPIO has been approved by FDA. 
As mentioned above, a large portion of iron oxide particles could be taken up by 
inflammatory cells following injection. In the in vitro study also performed by Williams 
et al [32, 49], it was shown that macrophage has the higher labeling efficiency than other 
cell types, and that larger particles performing greater labeling efficiency than smaller 
ones. Table 1.2 shows the percent uptake of MPIO by immune cell types.   
 
 
Table 1.2: Percent uptake of MPIO by immune cell types 
MPIO size % T cells % B cells % Macrophages % Splenocytes 
0.35 m 3.2 21.2 54 18 
0.90 m 2.8 9.3 73 16.6 
1.63 m 2.7 38.5 72 37 
The measurement was determined by fluorescence spectroscopy 24 hours after cell 
culture. From John B. Williams, et al. (2007) 
        
 
     
1.3 Inflammatory Response and Myocardial Infarction 
Cardiovascular disease remains the leading cause of death in developed countries, 
despite recent improvements due to advances in prevention, early diagnosis, and 
therapeutic and surgical interventions. Experimental evidence strongly supports the 
conclusion that inflammatory responses, accompanied by elevated levels of cytokines, are 
a common immunopathological feature following myocardial infarction.  These features 
may contribute to myocardial remodeling and functional outcome for the more than 7.2 
million American adults.  Triggers of cytokine release in the post-myocardial infarction 




and cytokine feedback amplification pathways.  These factors lead to inflammatory cell 
infiltration into the injured site which, in conjunction with hypo-perfusion due to low 
blood pressure and poor cardiac output sequelae, produces a positive feedback of the 
damaging responses. In spite of the established importance of inflammatory cell 
infiltration into the heart both prior to, and following, myocardial infarction, non-invasive 
monitoring strategies to assess localized inflammation in affected cardiac tissues are 
currently extremely limited.  Consequently, improvements in imaging techniques to 
visualize cellular infiltration would greatly advance monitoring of therapeutic effects 
relevant to both prevention and treatment of cardiovascular diseases. 
The findings in the cellular or molecular level provided by contrast agent enhanced 
MRI techniques also potentially supply an exciting platform to acquire better 
understanding of the cellular and molecular mechanisms of regulating the inflammatory 
response following myocardial injuries such as ischemia or infarction [50-52]. Based on 
the novel understanding, new strategies could be explored to reduce the deleterious 
remodeling following a MI by promoting effective cardiac tissue repair in cardiology. It 
is suggested that monocyte-derived macrophages and mast cells may produce cytokines 
and growth factors necessary for fibroblast proliferation and neovascularization leading 
to effective repair and scar formation [50]. Despite of the arguments that augmented 
macrophage homing and inflammatory cytokine production may lead to maladaptive left 
ventricular remodeling and functional deterioration following a MI [53], Leor and 
coworkers [54] showed improved scar thickening and cardiac performance. This was 
demonstrated by injecting human activated macrophages into the ischemic myocardium 




1.4 Research Objects  
It is critical to non-invasively evaluate pathophysiological changes in cardiovascular 
tissues so that prevention and treatment strategies can be implemented as early as 
possible. The early treatment can minimize or reverse damage after an infarct. The 
hypothesis for the research is that myocardial injury and cellular infiltration due to 
inflammatory processes can be quantified non-invasively and that myocardial deficits due 
to injury and development of inflammatory cell infiltration can be accurately monitored.  
Based on the hypothesis, the objectives of this research project include developing 
methods for non-invasive monitoring of inflammatory cell infiltration after myocardial 
infarction in a murine model.  Furthermore, the myocardial remodeling process was 
monitored by calculating the cardiac function and correlated with the cellular infiltration.  
First we injected the MPIO systemically into the mice and waited until the MPIO 
clearance from the blood pool occurred. A MI was then induced and the potential of 
MPIO-laden inflammatory cells being activated migrating and homing to the myocardial 
injury site was examined. The temporal response of MPIO-laden inflammatory cell 
infiltration into the MI site, as well as cardiac performance was assessed. Provided that 
the cell mobilization due to myocardial injury could be visualized with appropriate MRI 
technique, this study will shed light on the investigation of the temporal relationship 
between the myocardial inflammation and cardiac remodeling progression during the 











2.1 Animal Preparation 
 
Adult male C57Bl/6 mice (23.8±1.4 g; 6–11 weeks old) were used following the 
guidelines of the Animal Care and Use Committee and the Animal Health and Care 
Section of the Institute (Medical College of Georgia, Augusta, GA, USA). The animals 
were anesthetized with a mixture of medical air, oxygen (1:1), and 2.0% isoflurane 
(Abbott Laboratories, Abbott Park, IL, USA), positioned prone upon the animal cradle 
and maintained at 1.8±0.2% isoflurane level throughout MRI sessions. This protocol 
maintained a relatively constant respiration rate of 63±6 breaths per minute and heart rate 
of 437±58 beats per minute during the MRI experiment. 
In this study, the animals were divided into three experimental groups: 1) myocardial 
infarction group with MPIO injection (MI+MPIO, n = 7); 2) myocardial infarction group 
without MPIO injection (MI-MPIO, n = 6); 3) sham-operated group with MPIO injection 
(Sham+MPIO, n = 7). For the MI+MPIO and Sham+MPIO groups, the animals were de 
novo labeled via intravenous administration of Bangs particles (Bangs Laboratories, Inc., 
Fishers, IN, USA), a type of MPIO, at a dose of 0.04 mg Fe/g body weight. At 7 days 
post- MPIO injection, the MI+MPIO group underwent MI surgery via permanent ligation 
of the LAD while the Sham+MPIO group underwent open-chest operation without 
myocardial injury. This study was designed to investigate MPIO-labeled inflammatory 
cells, predominately macrophages, migrating to the injured site post MI. Therefore for the 




cleared out from the blood pool. This protocol reduced the possibility of cells that have 
been directly labeled in the blood pool migrating to the injury site or the local 
inflammatory cells in the heart endocytosing the circulating MPIO from the blood pool. 
The 7-day interval between the MPIO injection and surgery allows the particles to be 
cleared from the blood pool under the detectable level, minimizing potential signal 
reduction contribution from the blood pool.  
2.2 Contrast Agent 
The MPIO used in this study are Bangs particles with 1.63 m diameter. They have a 
magnetite core (42.5% weight) coated with a polymer. They also carry a Suncoast 
Yellow fluorescence label with a wavelength of excitation:emission = 540:600 nm. 
2.3 Blood Pool Measurement 
A blood pool study was performed to evaluate the MPIO blood pool kinetics. This 
aspect of the overall investigation was performed on 7 additional non-injured animals 
(25.3±3.4 g; 6-12 weeks old). Blood samples were obtained at various time points post-
MPIO injection and MPIO fluorescence intensity measured on a 2-D IVIS 100 Imaging 
System (Caliper Life Sciences, Hopkinton, MA, USA). One or two blood samples were 
taken from each mouse once respirations had stabilized after anesthetizing each animal 
with 1.0% isoflurane. First, a 27-gauge needle, 1-ml syringe and 0.5-ml tube were 
moistened with Heparin. Then 100 l of blood was removed by puncturing the needle 
into the left ventricle of the heart. A 50 l blood sample was then placed into the 96-well 
plate for fluorescence imaging. 




Animals were anesthetized with an intraperitoneal ketamine/xylazine cocktail and 
placed in a supine position. A midline cervical incision was made to intubate the trachea. 
The intubated mice were connected to a rodent ventilator (CWE Inc., Ardmore, PA, USA) 
and were ventilated at a respiratory rate of 90 breaths per minute. The chest was opened 
by middle thoracotomy at the upper sternum, between the fourth and fifth ribs. In the 
myocardial infarction study, myocardial infarcts were produced by permanently ligating 
the LAD. The LAD was ligated at a position approximate 1 mm below the left auricle 
with an 8-0 polypropylene monofilament suture (Ethicon Inc., Somerville, NJ, USA). 
This induced a detectable area of ischemia in the left ventricle. When the suture was tied, 
the heart turned pale and an arrhythmia was noted. The sham group underwent chest-
open procedures without ligation of the LAD. After surgery the mice were allowed to 
recover in a recovery chamber at 38 ºC. 
2.5 MRI 
MRI was performed 1 day before surgery as a baseline, and at 3 (D3), 7 (D7) and 14 
days (D14) post-surgery. Images were acquired on a horizontal 7.0-T, 21-cm MRI 
spectrometer (Bruker Instruments, Billerica, MA, USA) equipped with a micro-imaging 
gradient insert (950 mT/m).  A 35mm inner diameter volume coil was used to transmit 
and receive signal at 1H frequency (300 MHz). ECG and respiratory signals were 
monitored and used for gating with a physiological monitoring system (SA Instruments, 
Inc., Stony Brook, NY). Short-axis images were acquired through the left ventricle and 
perpendicular to the long axis of the heart using three pulse sequences: (1) A Gradient 
Echo sequence with Flow Compensation (GEFC) was performed to acquire the T2
*-




GEFC cine sequence was performed to acquire the movie of cardiac movement, by which 
cardiac indices were calculated to evaluate the cardiac function; (3) A Multiple Slices 
Multiple Echoes (MSME T2 map) sequence was performed to get the T2-weighted image 
and T2 map. The imaging parameters for the GEFC were: Echo time/Repetition time 
(TE/TR) = 4/120 ms; flip angle (FA) = 30o; Field of view (FOV) = 30 x 30 mm; Slice 
thickness = 1 mm; Matrix = 256 x 256 and 8 averages. The parameters for GEFC cine 
sequence were: TE/TR = 4/16 ms; FA = 25o; FOV = 30 x 30 mm; Slice thickness = 1 mm; 
Matrix = 128 x 128; 8 frames in one cardiac cycle and 8 averages. The parameters for 
MSME T2 map was: TR = 1000 ms; Average TE = 20 ms with 5 echoes in the echo train; 
FA = 180o; FOV = 30 x 30 mm; Slice thickness = 1 mm; Matrix = 256 x 256 and 4 
averages. All the three pulse sequences were gated by the ECG signal on the falling edge 
of the R-wave at the end-diastole, with the T2 map sequence additionally gated by the 
respiratory signal.  
2.6 Fluorescence Imaging 
After the terminal MRI session, the mice were sacrificed and perfused with 4% PFA. 
Then the heart was removed and fluorescently imaged on the same 2-D IVIS 100 
Imaging System used for the blood pool measurement. The MPIO have an outer coating 
of Suncoast Yellow fluorescence label with a wavelength of excitation:emission = 
540:600 nm. The wavelength used to acquire the fluorescence images was 
Excitation:Emission = 500-550:575-650 nm for the primary image and 
Excitation:Emission = 460-490:575-650 nm for the background image. The corrected 
image was obtained by subtracting the background image from the primary image. The 




f/stop = 2; FOV = 5 cm and subject height = 1.5 cm. Immediately after removal from the 
animal the heart was placed on the stage inside the imaging chamber with infarction site 
facing upwards. To ensure that the MPIO injection was successful, in vivo fluorescent 
imaging of the mice liver and spleen was performed immediately after Bangs injection. 
The rapid Bangs accumulation in the liver and spleen resulted in a strong fluorescent 
signal. The mouse was shaved and positioned supine on the imaging stage in order to 
acquire the signal from the liver and spleen. The imaging setup was as follow:  exposure 
time = 1 second; binning = 2; f/stop = 2; FOV = 12.5 cm; and subject height = 1.5 cm. 
2.7 Histology 
Following fluorescent imaging the heart underwent PFA fixation. After PFA fixation, 
the heart was cut into sections for staining and histological analysis. Hematoxylin and 
Eosin (H&E) staining was performed to examine the tissue integrity, F4/80 staining to 
monitor the inflammatory cells migrating into myocardium, and Prussian Blue staining to 
detect the existence of iron oxide particles taken up by macrophages. 
2.8 Image Processing 
Cardiac performance was evaluated using the left ventricular ejection fraction 
(LVEF). The LVEF was calculated through left ventricular end-diastolic volume 
(LVEDV) and left ventricular end-systolic volume (LVESV), which were determined 
from the endocardial contours at the end-diastole and end-systole phase respectively. The 
regions of interest (ROIs) for calculation were drawn on the continuous short-axis image 











Signal intensity (SI) and contrast-to-noise ratio (CNR) analysis was performed on 
GEFC short axis images using Paravision 4.0.1 software (Bruker Instruments, Billerica, 
MA, USA). Five ROIs, MIROI , adjROI , refROI , sepROI  and bkgROI , were delineated to 
calculate the normalized SI and CNR on the GEFC T2
*-weighted images. MIROI  was 
defined as the myocardial infarction region with wall thinning, corresponding to the area 
with akinetic contractility on the cine images. adjROI  was designated at the area adjacent 
to the MI site in the left ventricular free wall (LVFW). refROI was the reference 
designated at a relatively clean region remote to the MI site in the intact LVFW. 
sepROI was designated in the interventricular septum close to the MI site. bkgROI  was 
placed on the background to calculate the signal intensity of the background noise. CNR 
between the myocardial infarction region MIROI and the reference refROI  was defined 








                                                Equation 2 
 
MISI , refSI  and bkgSI  were the mean signal intensity of MIROI , refROI and bkgROI  
respectively. The signal intensity was normalized to the reference area, with the 



















SI                                           Equation 5 
 
adjSI  and sepSI  were the mean signal intensity of adjROI and sepROI  respectively.  
2.9 Statistical Analysis  
All data was presented as mean ± standard error of mean (SEM). To compare the 
difference of CNR values and LVEF values among the three experimental groups, two-
way repeated-measures ANOVA was used, followed by Bonferroni post-hoc test to 
specially compare two assigned groups. A linear regression was used to determine if a 
correlation existed between the inflammatory-cell infiltration represented by the CNR at 
the MI site and cardiac remodeling represented by the LVEF. The first order exponential 
curve fitting was used to estimate the half life of MPIO washout in the blood pool. The 











3.1 Blood Pool Kinetics 
It is critical to understand the blood pool kinetics of the MPIO in order to determine 
the proper timing to introduce an experimental myocardial infarction without having 
residual effects of the negative MRI enhancement from the circulating particles. Based on 
the optical imaging data shown in Figure 1, the signal intensity for the blood samples 
reaches a maximum within 30 seconds post-MPIO injection. Furthermore, MPIO was 
quickly washed out from the blood pool as the half life was less than 1 minute (T = 0.73 
minutes; r2 = 0.94).  Therefore, the 7-day interval between MPIO injection and MI was 
sufficient for allowing particles to clear from the blood pool, which minimized signal 
attenuation caused by particles otherwise remaining in the peripheral blood pool. In this 
manner, inflammatory cells mobilizing to the myocardial injury by remote recruitment 
were distinguished from the resident inflammation-activated immune cells. 
                            




3.2 MPIO-Labeled Inflammatory Cell Infiltration 
Both T2*-weighted images and T2 map were acquired and used for analysis to 
determine the extent to which infiltration of inflammatory cells into the MI site could be 
monitored using MPIO-enhanced MRI. As shown in Figure 2, gradual signal attenuation 
at the MI site was observed in the MI+MPIO group post-surgery. No detectable signal 
attenuation was observed at the corresponding site in either MI-MPIO or Sham+MPIO 
group. There was no significant difference at the corresponding site between the pre- and 
post-surgery images in all the groups. In order to prove that the pronounced signal 
attenuation around the MI site was caused by the infiltration of MPIO-laden 
inflammatory cells, the MRI findings were further validated with fluorescence imaging 
and histology.  
 
Figure 2: Longitudinal MRI. The T2
*-weighted images were acquired at baseline, 3, 7 




To demonstrate that the pronounced signal attenuation around the MI site was caused 
by infiltration of MPIO-laden inflammatory cells, the MRI findings were correlated with 
histology and fluorescence imaging. Figure 3 A and B are the montage heart slices by 
macroscopic images with 10x magnification from a representative MI+MPIO heart and a 
Sham+MPIO heart respectively. In Figure 3A, a considerable number of MPIO-labeled 
cells were localized at the MI and adjacent area as indicated by the arrows, while no 
MPIO-labeled cells were observed in the sham heart in Figure 3B. Comparison between 
the Prussian blue staining and MRI demonstrated the co-registered MPIO distribution. 
The hypo-intense area in the T2*-weighted image and area with dark spots in the T2 map 
co-localized well with each other and also with the iron accumulation in the Prussian blue 
staining. For the MI+MPIO group, as shown in Figure 3 C and D, the histology showed 
the co-localization of the Prussian blue and F4/80 staining, indicating that an appreciable 
amount of iron was incorporated in the macrophages. For the Sham+MPIO group, as 
shown in Figure 3 F and G, no F4/80 or Prussian blue positive cell was observed. For the 
MI-MPIO group, there were a considerable number of F4/80 positive macrophages 
around the MI site, while no Prussian blue stained cells were co-localized with them. It 
was observed a very small amount of iron scattered around the LVFW in the MI-MPIO 
group, which might be caused by the hemorrhage during the MI surgery. In the ex vivo 
fluorescent image shown in Figure 3 E and H, a strong signal observed at the MI region 
in the representative MI+MPIO heart (Figure 3E) indicated localized Bangs particles, 
while the Sham+MPIO heart (Figure 3H) lacked fluorescence signal enhancement. The 




potentially mobilize, infiltrate, and engraft into the myocardial injury site and cause 
significant signal attenuation in MRI T2*-weighted and T2-weighted images.   
 In this study, normalized signal intensity at the septum, MI site and the adjacent area, 
and CNR at the MI site were calculated and analyzed to quantify the infiltration of 
Figure 3: Histology images. The MI and Sham hearts were excised 7 days post-
surgery. The images A and B show the whole heart slices montaged with about 30 
macroscopic images (10x magnification). C and D are corresponding to the 
enlargement of the area boxed with the red lines in image A, and F and G to that in 
image B. C and F are Prussian blue staining for iron, D and G are F4/80 staining for 




MPIO-labeled inflammatory cells following myocardial injury. The definition for 
normalized signal intensity and CNR can be found in Section 2.8 equation 2-5.  
To evaluate the temporal variation of normalized signal intensity of various zones, the 
SNRs of different ROIs were calculated and then normalized to the SNR of the reference, 
which gives the results of equation 3 to 5 in Section 2.8. In the Sham+MPIO group, a 
false MI zone was designated in the region corresponding to that of the MI groups 
assuming existence of a MI site.  As shown in Figure 4, the MI+MPIO group demonstrate 
gradual signal attenuation at the MI site. The signal intensity dropped dramatically within 
one week post-MI and did not show much change between D7 and D14. The normalized 
signal intensity at the corresponding site in the two control groups did not change 
significantly over the experiment duration. For the normalized signal intensity at the 
adjacent zone, no signal attenuation was observed in the Sham+MPIO group, and little 
attenuation was observed in the two MI groups. This attenuation in the two MI groups 
may be due to the necrosis of the myocardium near the suture or the hemorrhage during 
the MI surgery, which could result in blood iron leakage. For the normalized signal 
intensity at the septum, it shows greater attenuation in the two MPIO injected groups 
(MI+MPIO and Sham+MPIO) than in the MI-MPIO group.  There was an obvious trend 
of gradual signal attenuation at the MI site, but no significant attenuation trend was 
observed at the adjacent zone or septum for the MI+MPIO group. This suggests that 
MPIO-laden inflammatory cells (mainly macrophages) mobilize and infiltrate to the MI 
site gradually, and can be monitored by MRI temporally.            
For the CNR analysis and comparison, as shown in the Table 3.1, the CNR post-




groups. The negative CNR values indicate a hypo-intensity at the MI zone. The more 
negative the CNR, the more attenuated the signal was at the MI zone relative to that in 
the healthy myocardium, and hence it indicated more MPIO-labeled inflammatory cell 
infiltration. The temporal characteristics of the CNR had a similar attenuation trend with 
that of the normalized signal intensity at the MI site. The CNR, which shows the 
difference between the MI zone and the reference, not only indicates the global 
mobilization and infiltration of MPIO-laden inflammatory cells into the MI site, but 
could also indicate the redistribution of the MPIO-laden inflammatory cells between the 
reference area and the MI site. Since the relatively stable signal intensity at the reference 
area was observed over the experiment duration, the later possibility of redistribution is 
eliminated. Hence the normalized signal intensity and CNR data at the MI site suggests a 
global inflammatory cell migration and infiltration following the myocardial infarction. 
 
Table 3.1:  Contrast-to-noise ratio values 
Note:  Values are mean  SEM. 
* denotes comparison between MI + MPIO and Sham + MPIO group; p(**)< 0.001.  




3.3   Temporal Features of Cardiac Remodeling 
Time  
MI + MPIO 
 (n = 7) 
Sham + MPIO 
 (n = 7) 
MI - MPIO
(n = 6) 
Baseline 0.40  1.03 -0.07  0.5 0.16  0.99 
Day 3 post-surgery -6.80  1.38 -0.88  1.16 ** -1.84  1.35 # 
Day 7 post-surgery -8.80  1.14 0.65  0.84 ** -1.86  1.22 ## 




LVEF, LVEDV, and LVESV were used to evaluate the cardiac performance and 
remodeling process post-surgery. As shown in Figure 5, LVEDV and LVESV increased 
markedly post-MI in the two MI groups, but with obviously different rates at different 
time intervals, determined by the slopes of the curve.  The most dramatic change in 
cardiac function took place within 1 week post-MI, which potentially reflected a fast left 
ventricular remodeling process.  After 7 days post-MI, the increase of both LVEDV and 
LVESV slowed down, which is reflected from the smaller curve slopes. The LVEF 
declined within one week post-MI, and gradually became stabilized afterwards.  The 
cardiac function for the sham group did not change much and stayed normal over the 
experiment duration.  The LVEF values are shown in Table 3.2. Two-way repeated-
measures ANOVA showed a significant difference among the 3 treatments (p<0.0001), 
and significant differences were also obtained between the sham and two MI groups at all 
the time points post-surgery (p<0.001) using Bonferroni post-hoc test. The information 
from the cardiac indices is important and necessary to monitor the cardiac performance 
and remodeling progression, especially when investigating changes during disease 
progression. The experimental data also indicates the consistence of using MRI as a tool 
to monitor the cardiac function. 
3.4 Correlation of Inflammatory Cell Infiltration and Cardiac Remodeling  
To examine the temporal relationship between the cardiac remodeling and the 
infiltration progression of the MPIO-laden inflammatory cells, a linear regression was 
used. The infiltration was represented by the CNR at the MI site, and the cardiac 
remodeling by the LVEF. The temporal MPIO-labeled inflammatory cell infiltration 




test the extent to which CNR was correlated to the LVEF. The LVEF and CNR at the MI 
site had similar characteristics of time dependence over the experimental time course 
(Figure 6). Both had rapid attenuation within one week following MI, before a reduction 
in the rate of attenuation. The correlation was examined by the linear regression of CNR 
versus LVEF, as shown in Figure 6. The result indicates a positive linear correlation 
(r2=0.98, slope=0.332) and suggests that the inflammatory cell infiltration post-MI was 
associated with the remodeling progression.  
 
Table 3.2: Left ventricular ejection fraction values 
Note:  Values are mean  SEM. 
* denotes comparison between MI + MPIO and Sham + MPIO group; p(**)< 0.001.  
# denotes comparison between MI - MPIO and Sham + MPIO group; p(##)<0.001.   
Time  
MI + MPIO 
 (n = 7) 
Sham + MPIO 
 (n = 7) 
MI - MPIO
(n = 6) 
Baseline 69.85  2.46% 71.61  0.81% 69.34  2.78% 
Day 3 post-surgery 49.68  3.50% ** 72.27  0.25%  51.26  4.01% ## 
Day 7 post-surgery 40.50  4.91% ** 73.57  1.43%  38.09  2.55% ## 








Figure 4: Normalized signal intensity at various zones. The MRI signal intensity was normalized to that at a reference designated at 




























Figure 6: Correlation of CNR and LVEF. The MPIO-labeled inflammatory cell infiltration was represented by CNR at the MI site, 
and cardiac remodeling by LVEF. On the left, CNR and LVEF were plotted in the same chart. Linear regression on the right 









Unlike other cell types that do not freely incorporate contrast agents without the 
existence of transfection agents, macrophages readily take up MPIO while keeping their 
ability to migrate and engraft into the inflammation sites. T cells, B cells and 
macrophages all have considerable capability of incorporating MPIO. However, the 
highest incorporation was observed in the culture of macrophages [32]. The characteristic 
of macrophages taking up MPIO paves the way to monitor and potentially quantify the 
migration and accumulation of macrophages by noninvasive MRI. It has been approved 
as an effective method to detect and monitor macrophage infiltration to the myocardial 
infarction site using iron oxide-enhanced MRI [55].  
Following the systemic administration, the iron oxide particles circulating in the 
blood pool are preferentially phagocytosed by immune cells before clearance within 
reticuloendothelial system [27]. Iron oxide particles are mainly accumulated in liver, 
spleen, bone marrow and lymph node [34, 36].    Knowing the clearance rate of the MPIO 
from the mouse blood pool provides a better understanding as to when the peripheral 
blood pool ceases to provide significant contrast enhancement and therefore an 
experimental myocardial infarction should be introduced. However, the half life of MPIO 
in the blood pool is dose dependent[8]. Hence it is necessary to first acquire the 
information of blood pool half life at a particular dose before designing a protocol to 




In this study the MRI was performed at three temporal points post-MI within the 
experimental course. Within one week post-MI, there are dramatic changes for both 
cardiac performance and inflammatory cell infiltration. The early phase might be 
important to study the inflammation following a MI. The signal attenuation was relatively 
steady after one week post-MI. Considering the high dose injected, however, the T2* 
effect might be saturated due to the large amount of iron accumulation. As a result, the 
further infiltration of MPIO-laden cells could not be differentiated at 14 days post-MI. 
The stabilized signal reduction potentially indicates that the iron was kept in the MI site 
for an appreciable period. Therefore the experimental design for future studies should 
include a longer time course in order to acquire information about the later phase of 
cardiac remodeling and potential washout of the iron from the infarcted heart. 
The macrophages are activated by myocardial injury and will recruit free MPIO, if 
any, directly from the blood pool [8]. In contrast to prior published results in which iron 
oxide particles were injected post-cardiac injury [55], in our study the MPIO were 
injected prior to myocardial infarction. The myocardial injury was induced after the 
clearance of iron oxide particles from the peripheral blood pool. Hence the local activated 
immune cells in the infarcted heart could not phagocytize the circulating MPIO directly 
from blood. Following the MI, the MPIO-labeled immune cells, in particular, 
macrophages would mobilize to the myocardial injury site. We can therefore distinguish 
the pre-labeled immune cells from the resident activated inflammation-related immune 
cells. Furthermore, the mobilization and infiltration of pre-labeled immune cells could be 




pre-labeling technique is potentially a better way to monitor disease progression in a pre-
clinic model.   
It is advantageous to study the inflammation and the function of inflammatory cells in 
the process of myocardial infarction by pre-labeling inflammatory cells de novo as 
compared to injecting in vitro labeled cells directly into the infarcted heart. In the in vitro 
cell-labeling technique, the functionality of labeled cells might be affected due to the in 
vitro labeling environment. An appreciable number of cells might die during or after the 
injection process. Furthermore, in the case of cardiac study, the injection directly to the 
myocardial infarction and adjacent zones has a potential risk to injure the myocardium 
further and cause irreversible damage. By using the de novo labeling method, however, a 
variety of cell types might take up the iron oxide particles instead of one specific cell type. 
Hence the potential disadvantage of the current study is the non-specific labeling where it 
unavoidably affects the specificity of the study in regard to a specific cell type, e.g. 
macrophages.   
To quantify labeled-cell infiltration more accurately in the MRI, novel methods are 
warranted other than using the SNR and CNR as representative indices. SNR and CNR 
have intrinsic variation due to the fluctuation of the magnetic resonance spectrometer 
during the experimental time course and also have dependence on the individual 
magnetic resonance system and imaging protocol implementation. Furthermore, the SNR 
and CNR calculated through the mean signal intensity of chosen ROIs, generally 
represent the density of accumulated iron oxide particles other than any information 
regarding spread or number of labeled cells over the infarction site. More quantitative 




Moreover, the dose of MPIO warrants further optimization. Excessive dose may lead to 
MPIO saturation at the MI zone while an insufficient dose may result in an undetectable 
number of MPIO-laden inflammatory cells, both leading to images with dark spots that 










In this experiment, the inflammatory cell migration following myocardial infarction 
was monitored using non-invasive MRI technique. First, the blood pool kinetics of the 
MPIO, Bangs, was examined and the half life of the MPIO clearance from the blood pool 
was estimated. The 7-day interval between the injection of the MPIO and the induction of 
myocardial infarction allowed for complete clearance of the MPIO from the blood pool, 
minimizing the signal reduction contribution from the circulating MPIO otherwise 
remaining in the blood pool.  
Second, the infiltration of labeled inflammatory cells into the MI heart was studied. 
The gradual signal attenuation was observed at the MI site in the MI+MPIO group using 
MRI. The normalized signal intensity and CNR differences were significant between the 
MI+MPIO group and the two control groups. The MRI findings were further validated by 
the fluorescence imaging and histology, in which localized MPIO were indicated and 
correlated well with the hypo-intense area in the T2*- and T2-weighted MRI. Furthermore, 
histology results indicated considerable numbers of cells localized with Bangs were 
macrophages. However, other cell types also potentially exist.   
Third, the temporal features of left ventricular cardiac function were examined. The 
decrease of LVEF, increase of LVEDV and LVESV post MI indicated a cardiac 
remodeling following myocardial infarction. These indices could be important for 
monitoring the cardiac remodeling in the study of disease progression.    




Last, to study the temporal correlation between cardiac remodeling and the MPIO-
labeled inflammatory cell infiltration, the linear regression was performed between LVEF 
and CNR at the MI site. The results showed a positive correlation, which demonstrated 
that the MPIO-labeled inflammatory cells migrated and engrafted to the MI site with the 
progression of cardiac remodeling.  
Overall, the inflammatory cells migration following MI could be tracked using the 
MPIO-enhanced MRI technique noninvasively and temporally. Normalized signal 
intensity and CNR at the MI site could be used as indices to monitor and quantify the 







Table A.1: MI+MPIO group LVEF data 
Mouse Number Baseline D3 D7 D14 
MI 1 72.55% 59.14% 56.12% 61.39% 
MI 2 65.48% 49.69% 55.22% 55.64% 
MI 3 62.43% 42.19% 31.51% 31.30% 
MI 4 68.39% 34.36% 24.41% 25.58% 
MI 5 68.18% 57.77% 50.26% 34.51% 
MI 6 82.80% 47.01% 31.37% 28.03% 
MI 7 69.09% 57.60% 34.61% 44.09% 
Mean 69.85% 49.68% 40.50% 40.08% 
SEM 2.46% 3.50% 4.91% 5.29% 
  
 
Table A.2: MI-MPIO group LVEF data 
Mouse Number Baseline D3 D7 D14 
MI Control1 NA 56.32% 37.06% 47.64% 
MI Control2 64.05% 36.88% 31.83% 28.32% 
MI Control3 68.30% 41.35% 32.53% 35.13% 
MI Control4 62.16% 52.75% 48.15% 46.43% 
MI Control5 80.81% 66.11% 44.50% 56.16% 
MI Control6 71.40% 54.16% 34.44% 46.85% 
Mean 69.34% 51.26% 38.09% 43.42% 






Table A.3: Sham+MPIO group LVEF data 
Mouse Number Baseline D3 D7 D14 
Sham 1 68.23% 71.79% 71.29% 77.81% 
Sham 2 70.30% 72.74% 73.87% 75.02% 
Sham 3 75.03% 
68.54% 75.80% 70.25% 
Sham 4 72.53% 72.98% 70.52% 68.42% 
Sham 5 71.09% 67.27% 72.65% 70.53% 
Sham 6 72.76% 72.38% 80.81% 85.16% 
Sham 7 71.34% 72.83% 70.02% 69.91% 
Mean 71.61% 72.27% 73.57% 73.87% 




















































MI 1 15.02 16.24 6.80 15.02 1.22 12.35 9.35 10.01 15.44 -6.09 20.00 6.85 12.75 18.59 -11.74 22.02 10.64 12.76 21.21 -10.56 
MI 2 14.16 16.16 8.88 14.16 2.00 17.67 12.67 9.46 15.95 -3.28 12.15 5.66 8.84 13.58 -7.93 14.10 6.08 12.42 17.56 -11.48 
MI 3 14.81 14.13 10.34 17.21 -3.07 22.28 19.99 10.20 23.65 -3.66 15.11 9.85 4.79 15.38 -5.53 22.01 9.09 7.42 18.76 -9.67 
MI 4 17.37 15.78 5.88 18.11 -2.33 16.90 4.84 8.84 17.36 -12.52 12.05 9.14 8.83 14.78 -5.64 11.02 9.70 6.73 17.17 -7.47 
MI 5 14.09 25.13 10.14 20.10 5.03 22.94 13.95 9.92 20.44 -6.49 17.19 8.21 10.11 17.39 -9.17 18.37 9.74 7.37 15.58 -5.84 
MI 6 16.95 19.80 5.99 20.30 -0.50 11.68 3.70 9.12 14.79 -11.09 23.55 5.26 10.32 18.94 -13.67 27.23 6.38 9.95 19.70 -13.33 
MI 7 22.94 24.56 23.59 24.13 0.43 23.70 19.81 11.38 24.27 -4.46 22.72 10.32 11.89 18.26 -7.94 20.82 13.29 6.81 24.77 -11.48 
Mean 16.47 18.83 10.23 18.43 0.40 18.22 12.04 9.85 18.84 -6.80 17.54 7.90 9.65 16.70 -8.80 19.37 9.27 9.07 19.25 -9.98 




Table A.5: MI-MPIO group SNR and CNR data 
Mouse 
Number 









































MI Ctl1 NA NA NA NA NA 23.85 23.89 18.68 21.28 21.79 22.20 26.56 23.44 24.48 25.55 23.80 26.33 21.48 19.34 28.02 
MI Ctl2 37.62 34.51 31.21 34.16 34.61 32.97 34.22 29.16 35.97 32.79 25.98 28.93 31.48 19.94 31.74 16.15 13.12 11.17 24.13 21.38 
MI Ctl3 21.26 22.02 18.69 20.83 27.99 26.53 24.73 25.18 24.69 24.74 21.26 22.02 18.69 20.83 18.49 24.44 24.02 22.51 24.65 26.20 
MI Ctl4 28.13 30.48 28.78 20.84 23.26 25.33 25.79 26.30 27.23 29.64 16.97 22.87 25.14 27.24 24.48 22.41 21.68 24.66 24.05 23.26 
MI Ctl5 13.87 13.79 13.39 6.71 16.46 26.48 26.62 25.28 23.59 30.23 29.25 28.29 24.15 22.19 27.87 17.76 27.49 24.08 22.86 28.43 
MI Ctl6 14.34 13.95 13.46 9.21 13.78 30.31 30.30 32.47 25.74 37.36 21.95 22.53 24.16 14.73 28.19 13.81 12.31 17.54 6.25 16.27 
Mean 23.05 22.95 21.10 18.35 23.22 27.58 27.59 26.18 26.42 29.43 22.94 25.20 24.51 21.57 26.05 19.73 20.83 20.24 20.22 23.93 




Table A.6: Sham+MPIO group SNR and CNR data 
Mouse 
Number 









































Sham 1 13.02 13.73 6.18 14.17 -0.44 14.98 19.20 10.23 18.74 0.46 20.84 27.40 15.86 26.37 1.04 17.41 19.52 17.41 19.72 -0.21 
Sham 2 12.95 18.61 6.50 19.38 -0.77 24.17 22.10 9.85 26.10 -4.00 25.82 28.16 10.93 30.26 -2.10 22.42 23.52 21.70 21.70 1.82 
Sham 3 22.43 22.82 5.38 23.17 -0.34 30.54 26.41 14.33 31.82 -5.41 26.87 28.65 11.55 29.82 -1.17 31.01 34.26 13.92 36.22 -1.96 
Sham 4 26.19 29.17 14.54 29.89 -0.72 26.89 27.83 19.19 25.17 2.66 26.99 30.20 22.62 26.01 4.19 30.96 33.93 19.85 33.96 -0.02 
Sham 5 25.56 26.81 22.76 28.03 -1.22 27.11 31.10 17.69 29.85 1.26 22.58 26.91 24.42 27.59 -0.68 26.37 30.97 24.53 30.77 0.19 
Sham 6 9.69 30.75 14.00 30.56 0.19 21.87 22.61 18.58 25.07 -2.46 23.98 29.95 22.25 27.26 2.68 27.99 25.59 21.62 26.34 -0.76 
Sham 7 23.37 27.71 22.89 24.93 2.77 23.09 32.81 25.47 31.48 1.33 21.10 32.42 20.04 31.84 0.59 24.17 32.96 23.14 32.83 0.13 
Mean 19.03 24.23 13.18 24.30 -0.07 24.09 26.01 16.48 26.89 -0.88 24.03 29.10 18.24 28.45 0.65 25.76 28.68 20.31 28.79 -0.12 
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